Anna Protopapas is the founder of Mersana Therapeutics. Mersana Therapeutics has raised $85M in total funding. Latest round: Series C.
Anna Protopapas is a veteran biotech executive currently serving as the CEO of Flare Therapeutics, a clinical-stage biotechnology company focused on developing precision medicines by targeting transcription factors. She was appointed CEO in June 2026, coinciding with the company's $85 million Series C financing. Prior to Flare Therapeutics, she was the President and CEO of Mersana Therapeutics from 2015 until September 2023, leading its transition to a publicly traded, clinical-stage entity. She also held leadership roles at Millennium Pharmaceuticals, a subsidiary of Takeda.
Full founder directory · Investor directory · Company funding database · Fundraising library